Key Takeaways
- Margin recovery story intact: EBITDA margin improved 150 bps YoY to 13.7% in Q4, and full-year FY24 margin reached 17.7%, driven by lower raw material costs and easing US price erosion.
- India business hit a one-off air pocket: Domestic revenue declined YoY in Q4 due to a high base from the prior year's flu outbreak and a 2.2% degrowth in the anti-infective market; management calls it a one-off and guides 10% domestic growth for FY25.
- US business faces near-term friction: Q4 US sales dipped to $74–$75 million from $80 million+ on seasonality and supply issues that triggered ₹30 crores in service-level penalties for the quarter. Management expects the penalty situation to improve and guides 7%–8% growth from new launches.
- Biosimilar CDMO is the big strategic bet: A US plant is being built to capture CDMO demand shifting away from Chinese players like Wuxi Biologicals, with revenue expected from Q4 FY25 or Q1 FY26 and operational expenses ramping to ₹120–130 crores in FY26.
- What to watch next quarter: Whether the India business rebounds from its Q4 decline, the pace of reduction in US supply-chain penalties, and any update on the Enzene US plant's order book and timeline.
India Business: The One-Off Decline and Recovery Bet
- Q4 decline explained: India business saw a YoY decline driven entirely by a high base in Q4 FY23, when a flu outbreak had boosted sales, and by the anti-infective market itself degrowing 2.2% in the quarter, an unusual trend.
- Anti-infective underperformance vs market: Alkem's anti-infective portfolio underperformed the already-weak market due to channel inventory normalization in a sluggish demand environment and the company's regional dependency on geographies that were hit harder.
- Therapies that outperformed: The company outperformed the IPM in antidiabetic, derma, GI, and VMN therapies, and improved its ranking in antidiabetic, cardiac, and respiratory segments.
- Chronic mix as margin lever: The chronic portfolio is expected to cross 20% of the domestic mix in the near-to-mid term, and since chronic therapies carry higher margins, this shift will contribute positively to overall margin improvement.
- Trade generics stable: The trade generic business is growing at a similar pace as the Rx business, with contribution stable at 20%–21%, and margins are now within 1%–2% of the corporate average as operating leverage kicks in.
- Volume-led growth model: Management is very bullish on India growth, banking on strong volume growth driven by its large field force; 70% of the portfolio has both price and volume levers, while the 30% NLEM portfolio is driven purely by volumes.
Dr. Vikas Gupta: "my belief is that it's a one-off. If you will see even the IPM and the anti-infective market for Q4 has degrown at around 2.2% which is a very unusual trend."
US Business: Stabilized Pricing, Supply-Chain Friction
- Q4 revenue dip: US sales fell to $74–$75 million from $80 million+ in earlier quarters, attributed to seasonality and one-off supply issues that impacted one or two months.
- Pricing has bottomed out: Price erosion seen in previous years has come down, and management believes prices are more or less bottomed out for many products, citing widespread US drug shortages that are now translating into Alkem's numbers.
- Service-level penalties a material drag: Supply-chain issues caused back orders, resulting in service-level penalties of ₹30 crores in Q4 and ₹120 crores for the full year. Management has ramped up the supply chain and expects the penalty situation to improve with every passing quarter.
- Launch-driven growth in FY25: The company plans 6–7 new launches and one relaunch in FY25, contributing an estimated 7%–8% growth; all new launches are planned from the Daman site, not from the Baddi site that received FDA observations.
- Baddi FDA observations contained: The Baddi site had a few US FDA observations, but management states none were very significant and there were no data integrity issues; they are hopeful of addressing all issues.
- Generic Suprep launched: The generic Suprep product has just been launched in the US market and is picking up.
Dr. Vikas Gupta: "We every day read reports in newspapers that US is going through a drug shortage for many products. For that to happen, the products need to be available over there. And I think it's translating even in our numbers where we are seeing the prices getting more or less bottomed out for many products."
Enzene Biosimilars & US CDMO: The Strategic Bet
- US CDMO plant rationale: The plant is being set up to capture CDMO business in the US market, where geopolitical pressures have reduced business for companies like Wuxi Biologicals, creating an opportunity for Alkem to offer a cost-arbitrage proposition with part of the process done in India.
- Revenue timeline: Revenue from the US plant is expected from Q4 FY25 or Q1 FY26; the plant will be ready in the second half of the current year.
- Order book already building: Alkem has started building an order book with customers ready to work with them once the plant is operational.
- Operational expense ramp: The US plant will incur ₹30–40 crores in operational expenses in the current year, rising to around ₹120–130 crores in FY26.
- Breakeven pushed out: Enzene had achieved breakeven for India-only operations, but with the new US plant investments, consolidated breakeven will take a while longer.
- Client-funded R&D: The US plant will not require much R&D investment from Alkem; clients will invest, as it is more of a contract manufacturing service.
- Biosimilar portfolio: The biosimilar business now has a portfolio of seven products, with close to four assets being worked on for the global market, though no biosimilar launches are planned for FY25.
Dr. Vikas Gupta: "It's to meet up on the CDMO business that we have in the US market. So, there were companies like Wuxi Biologicals who are really catering to this market and their multi-billion dollar business as far as this business was concerned. Now with US facing pressures because of geopolitical reasons, so some of these companies are not doing the kind of business that they were doing and which threw up an opportunity for players like us to consider, entry into the CDMO business as far as U.S. market is concerned."
Margin Drivers and Sustainability
- Gross margin improvement sustainable: The improvement is a mix of continuous day-to-day initiatives including supply chain efficiencies and raw material procurement, and management expects it to be sustainable.
- PenG price upside: Alkem is one of the largest consumers of PenG, and if PenG prices ease as anticipated, the margin profile would improve further, though no significant change has been seen yet despite a large Indian player starting production.
- API prices stable: Favorable API prices drove operational improvement, and prices are now stable; raw material prices are expected to remain stable unless a Black Swan event occurs.
- R&D spend rising: R&D spend is forecast to move from 4.1% to 4.5%–5% of sales, including clinical trials for the biosimilar portfolio, which will absorb some of the gross margin gains at the corporate level.
- Corporate EBITDA flat by design: Management expects business-unit-level EBITDA might improve, but corporate-level EBITDA may stay at current levels due to investments for future growth, with only 20–30 bps improvement guided over FY24's 17.7%.
Dr. Vikas Gupta: "I can tell you is that we have one of the largest consumers of PenG and if Pen G prices ease out, we will be happier than anyone else."
New Business Ventures
- Medical devices entry: Alkem has floated a new company for medical devices, a mix of organic and potentially inorganic, starting with the domestic market; management describes it as an important line of business but provided no timeline for materiality.
- Ophthalmic division: A very recent launch, growing with every passing month but currently very small; the market size is large with fewer players, and new launches are planned in this therapy.
- M&A appetite: Management states they are "very hungry" for acquisitions and are looking for the right opportunity at the right price.
- Vision for new businesses: Alkem's stated vision is to enter the top players in any segment they enter, as they have done historically.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | ~10%, in line with market growth, largely volume-led from domestic business | FY25 |
| Domestic business growth | 10% growth | FY25 |
| US new launch contribution | 6–7 launches, one relaunch, contributing ~7%–8% growth | FY25 |
| EBITDA margin | More or less in line with FY24's 17.7%, with maybe 20–30 bps improvement | FY25 |
| R&D spend | 4.5% to 5% of sales, including biosimilar clinical trials | FY25 |
| CAPEX | ₹600 to ₹700 crores | FY25 |
| Tax rate | 13% to 15% for next two years; rising to ~25% in FY27 when second tax benefit ends | FY25–FY27 |
| Enzene US plant operational | Plant ready in H2; revenue from Q4 FY25 or Q1 FY26 | FY25–FY26 |
| Enzene US plant opex | ₹30–40 crores in FY25, rising to ₹120–130 crores in FY26 | FY25–FY26 |
| US supply-chain penalties | Expect to bring down service-level penalties | FY25 |
| Chronic portfolio contribution | Expected to cross 20% | Near-to-mid term |
| Trade generic contribution | Remain in 20%–22% range | Going forward |
| Biosimilar launches | No launches in FY25; maybe some next year | FY26 |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue from operations | Not explicitly stated for Q4; FY24 international business crossed ₹4,000 cr |
| EBITDA margin | 13.7%, improved 150 bps YoY from 12.2% |
| Net profit after tax | ₹294 cr; adjusted PAT growth roughly 54% YoY excluding ₹120 cr deferred tax derecognition in Q4 FY23 |
| Net profit before tax (FY24) | >₹2,000 cr, first time crossing this threshold |
| Gross margin | Management expects to maintain within current range; Q4 saw significant enhancements backed by lower raw material costs |
| R&D spend | 4.1% of revenue in FY24; guided to 4.5%–5.0% going forward |
| Cash generated (FY24) | ~₹1,400 cr |
| Net cash position | ~₹3,550 cr |
| CAPEX guidance (FY25) | ₹600–700 cr, including ~₹400 cr for new US facility and ₹80–100 cr maintenance CAPEX |
| India business growth guidance (FY25) | ~10%, in line with IPM or plus one cent; 3% from price, 1–2% from new launches, balance volume-led |
| US business quarterly sales | $74–$75 million, down from $80 million+ in prior quarters due to seasonality and supply issues |
| US business price erosion | Stabilized at low single digit |
| US business new launches (FY25) | 6–7 launches expected, contributing 7–8% growth |
| ANDA approvals in Q4 | 2 |
| Trade generic contribution to domestic business | ~20%, within 20–21% range; expected to remain 20–22% going forward |
| Chronic portfolio contribution | 17–18% of domestic business; expected to cross 20% in near-to-mid-term |
| Biosimilar portfolio (domestic) | 7 products launched; contributes ~5% of overall domestic business |
| Field force headcount | ~12,000 |
| Service level penalties (US supply chain) | ₹30 cr in Q4; ₹120 cr for full year |
| Tax rate guidance | 13–15% for next two years; increasing to ~25% from FY27 |
| Enzene US plant operational expenses (FY25) | ₹30–40 cr; annualized ~₹120–130 cr in FY26 |
| Anti-infective therapy growth expectation (FY25) | 7–8% |
| IPM anti-infective market growth (Q4 FY24) | Degrown ~2.2% |